Achieving allocative efficiency in healthcare: Nice in theory, not so NICE in practice?

PharmacoEconomics

Volumn 32, Issue 4, 2014, Pages 315-318

  Paulden, Mike ^a   McCabe, Christopher ^a   Karnon, Jonathan ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUTHORITY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE PRACTICE; HEALTH CARE SYSTEM; HUMAN; MEDICAL TECHNOLOGY; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; REVIEW; THEORY; ECONOMICS; HEALTH CARE DELIVERY; ORGANIZATION AND MANAGEMENT;

BIOMEDICAL TECHNOLOGY; DELIVERY OF HEALTH CARE; HUMANS; REIMBURSEMENT MECHANISMS;

EID: 84897501016     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0146-x     Document Type: Review

References (15)

1. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics. 2008;26(9):733-44. http://www.ncbi.nlm.nih.gov/pubmed/18767894. Accessed 2 Dec 2010.
2. Claxton K, Briggs A, Buxton MJ, et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ. 2008;336(7638):251-4.
3. Sculpher M, Claxton K. Real economics needs to reflect real decisions: a response to Johnson. Pharmacoeconomics. 2012;30(2):133-6. doi: 10.2165/11596660-000000000-00000.
4. Griffin S, Claxton K, Sculpher M. Decision analysis for resource allocation in health care. J Health Serv Res Policy. 2008;13(Suppl 3):23-30. doi: 10.1258/jhsrp.2008.008017.
5. Culyer A, McCabe C, Briggs A, et al. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. J Health Serv Res Policy. 2007;12(1):56-8. doi: 10.1258/ 135581907779497567.
6. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. London: NICE; 2013. http://publications.nice.org. uk/pmg9. Accessed 28 Feb 2014.
7. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the NICE cost effectiveness threshold final report, University of York. 2013. http://www.york.ac.uk/media/che/documents/ papers/researchpapers/CHERP81-methods-estimation-NICE-costeffectiveness- threshold-%28Nov2013%29.pdf. Accessed 28 Feb 2014.
8. Garner S, Littlejohns P. Disinvestment from low value clinical interventions: NICEly done? BMJ. 2011;343:d4519. doi: 10.1136/bmj.d4519.
9. Pekarsky B. Trust, constraints and the counterfactual: Reframing the political economy of new drugs. 2012;(April) [thesis]. http://digital.library. adelaide.edu.au/dspace/bitstream/2440/79171/3/02whole.pdf. Accessed 28 Feb 2014.
10. Elshaug AG, Watt AM, Mundy L, Willis CD. Over 150 potentially low-value health care practices: an Australian study. Med J Aust. 2012;197(10):556-60. doi: 10.5694/mja12.11083.
11. Karnon J, Caffrey O, Pham C, et al. Applying risk adjusted cost-effectiveness (RAC-E) analysis to hospitals: estimating the costs and consequences of variation in clinical practice. Health Econ. 2013;22(6):631-42. doi: 10.1002/hec.2828.
12. ABIM Foundation. Choosing wisely. 2014. http://www.choosingwisely.org/. Accessed 12 Feb 2014.
13. Institute for Healthcare Improvement. The IHI Triple Aim. 2013. http://www.ihi.org/engage/initiatives/tripleaim/pages/default.aspx. Accessed 28 Feb 2014.
14. Porter ME. What is value in health care? N Engl J Med. 2010;363(26):2477-81. doi: 10.1056/NEJMp1011024.
15. Eckermann S, Pekarsky B. Can the real opportunity cost stand up: displaced services, the straw man outside the room. Pharmacoeconomics. Epub 2014 Feb. doi: 10.1007/s40273-014-0140-3.